Infective endocarditis (IE) caused by Streptococcus agalactiae (group B Streptococcus, GBS) is a serious disease. Ivanova-Georgieva et al. [1] recently demonstrated the similarities and differences in the clinical characteristics of leftsided IE caused by GBS and S. aureus. Their results underscored the severity of GBS IE, confirming findings of prior studies [2, 3] .
Discussion of the optimal antibiotic treatment for (native valve) GBS IE leads to the question of whether combination therapy with adjunctive gentamicin treatment is as effective as beta-lactam monotherapy. This question applies to IE caused by other beta-hemolytic streptococci, also [4] . In the study by Ivanova-Georgieva et al. [1] , patients with GBS IE were treated with adjunctive aminoglycosides significantly more often (26 of 39 [66.7%]) than those with S. aureus IE (122 of 313 [39%], p = 0.002). In a recent study by El Rafei et al. [5] on IE caused by beta-hemolytic streptococci (49 cases, 39 [80%] of them caused by GBS), combination therapy was administered in 25 (58.1%) of 43 IE cases and beta-lactam monotherapy in 18 (41.9%). The proportion of patients treated with adjunctive gentamicin was understandable considering the IE recommendations in the European and US guidelines for IE [6, 7] . However, given the relatively small number of GBS IE cases in each of the published series [1] [2] [3] and the rarity of the disease [1] , solid evidence to answer this question is unlikely to be generated in the near future. Therefore, it is worthwhile to review the data on this topic on historical, clinical, microbiological, and emotional levels.
In 2015, the authors of the European guidelines stated that Bgentamicin should be given for 2 weeks^for IE caused by beta-hemolytic streptococci [6] . This recommendation was added to the 2009 guidelines without providing a rationale. In 2002, Lefort et al. [8] compared the antibiotic treatment for IE due to beta-hemolytic streptococci (56 cases, 34 [61%] of them caused by GBS) with that for IE due to Streptococcus milleri. Combination therapy with adjunctive gentamicin was given in 51 of 56 (91%) and 27 of 29 (93%) cases, respectively, which prevented the authors from drawing a conclusion on the treatment outcome with beta-lactam monotherapy. In 2015, the American Heart Association (AHA) recommended that clinicians should Bconsider^the addition of gentamicin to penicillin or ceftriaxone for at least the first 2 weeks of a 4-to 6-week course of antimicrobial therapy for group B, C, and G streptococcal IE [7] . The statement is referenced with two publications [9, 10] and in line with the 2005 AHA statement on IE [11] . While one of the two citations refers to the 1998 Infectious Diseases Society of America (IDSA) statement [9] , the other points towards the publication of two case reports of IE due to group G Streptococcus and a literature review [10] . In their 1988 literature review, Smyth et al. [10] compared 20 IE cases treated with beta-lactam antibiotic alone or in combination with an aminoglycoside for less than 14 days with 12 IE cases treated with adjunctive aminoglycosides for 14 days or more. They also compared 22 IE cases with betalactam antibiotic alone or in combination with an aminoglycoside for less than 28 days with 10 IE cases treated with adjunctive aminoglycosides for 28 days or more. Although the analyses for complications or outcome revealed no significant differences, the authors supported the view that patients with group G streptococcal endocarditis should be treated with combination therapy for at least 28 days [10] . Overall, there are no clinical data demonstrating that combination therapy with adjunctive gentamicin is superior to beta-lactam monotherapy for IE caused by betahemolytic streptococci.
Microbiological rationales behind the combination therapy are results from in vitro and animal experimental GBS infection studies suggesting synergism or a better bactericidal effect [5] . These studies were mainly initiated because of the worrisome mortality rates in neonates with GBS sepsis and meningitis before the implementation of intrapartum prophylaxis for GBS colonized women [12] . These studies suggested a trend towards faster killing of planktonic GBS in vitro, but remain inconclusive in vivo ( Table 1) 
7 colony forming units [CFU]/mL) is up to 100,000 times higher than that found in human sepsis (e.g., 1-100 CFU/mL) [22] . The antibiotic concentrations administered to patients are significantly higher than those used in experimental assays (e.g., 0.5× to 4× the minimum inhibitory concentration [MIC]). Recently, performed time-kill assays indicated that the addition of gentamicin to penicillin contributes to faster killing of planktonic GBS without fulfilling the criteria for synergism. The in vitro effect of faster killing was seen only at low penicillin concentrations and only within the first few hours of the assay [23] . When human blood products (serum, neutrophilic granulocytes, or whole blood from healthy volunteers [≥ 65 years]) were added to experiments, no beneficial effect of adjunctive gentamicin was seen [24] . Thus, the available in vitro data and data from animal experiments on faster GBS killing or synergism do not justify prolonged gentamicin treatment in GBS IE.
Another microbiological rationale for combination therapy may be the higher penicillin MIC values of GBS in comparison to those of group A Streptococcus. The relevance of the penicillin MIC for implementing adjunctive gentamicin treatment has not been evaluated for beta-hemolytic streptococci.
Viridans group streptococci and Streptococcus gallolyticus (bovis) are considered susceptible to penicillin when the MIC is ≤ 0.125 mg/L. According to the European guidelines and the AHA statement, IE caused by these microorganisms can be treated with adjunct gentamicin to shorten the total treatment duration from 4 to 2 weeks [6, 7] . Such a recommendation does not exist for beta-hemolytic streptococci. Only a small minority of GBS have a higher MIC than 0.125 mg/L (5 [0.15%] of 3261 GBS in European Committee on Antimicrobial Susceptibility Testing) [25] .
In clinical practice, the tendency is to administer more and several antibiotics when a patient has severe disease. In our study with 74 GBS IE cases, a logistic regression analysis suggested that patients receiving aminoglycosides had a higher probability of developing heart failure than did those who did not receive them [26] . This indicated that aminoglycosides were given more frequently to patients with severe clinical manifestations of IE. Similarly, in the study by El Rafei et al. [5] , combination therapy was significantly more frequently found in patients with an intra-cardiac abscess (10 of 25 [40%] versus 2 of 18 [11%] in the beta-lactam monotherapy group, p = 0.030). The study by Ivanova-Georgieva et al. [1] may help us to recall the previous treatment concepts of S. aureus IE in the absence of prosthetic valves, a disease that is as severe as GBS IE. In the 1980s, both right-and leftsided IE due to S. aureus were commonly treated with an antistaphylococcal penicillin for 4-6 weeks plus aminoglycosides for the first 2 weeks [27, 28] . Over the next years, trials comparing a cell-wall active agent with and without gentamicin demonstrated that combination therapy reduced the duration of bacteremia by approximately 1 day compared with monotherapy, but without reducing the mortality or frequency of cardiac complications [29] . The price for this effect was increased nephrotoxicity. In 2005, the AHA recommended the optional addition of gentamicin (3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses) for the first 3 to 5 days of therapy for left-sided S. aureus IE [11] . With this adjunctive gentamicin regimen, significant renal dysfunction without additional clinical benefit for S. aureus IE treatment was observed in the following years [30, 31] . Current guidelines for staphylococcal native valve IE do not recommend gentamicin [6, 7] .
Considering the lack of evidence for adjunctive gentamicin therapy in GBS IE and the clinical similarities of S. aureus IE and GBS IE, as shown by Ivanova-Georgieva et al. [1] , it is time that the adjunctive gentamicin recommendation for the treatment of native valve IE caused by beta-hemolytic streptococci follow those for IE caused by S. aureus: The recommendation should be abandoned.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
